AU2016353348A1 - Heterocyclic compounds for the treatment of disease - Google Patents
Heterocyclic compounds for the treatment of disease Download PDFInfo
- Publication number
- AU2016353348A1 AU2016353348A1 AU2016353348A AU2016353348A AU2016353348A1 AU 2016353348 A1 AU2016353348 A1 AU 2016353348A1 AU 2016353348 A AU2016353348 A AU 2016353348A AU 2016353348 A AU2016353348 A AU 2016353348A AU 2016353348 A1 AU2016353348 A1 AU 2016353348A1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- compound
- formula
- another embodiment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*S(C)(C)c1nnc(*(C)C)[o]1 Chemical compound C*S(C)(C)c1nnc(*(C)C)[o]1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021202945A AU2021202945B2 (en) | 2015-11-13 | 2021-05-10 | Heterocyclic compounds for the treatment of disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255041P | 2015-11-13 | 2015-11-13 | |
| US62/255,041 | 2015-11-13 | ||
| PCT/US2016/061676 WO2017083756A1 (en) | 2015-11-13 | 2016-11-11 | Heterocyclic compounds for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021202945A Division AU2021202945B2 (en) | 2015-11-13 | 2021-05-10 | Heterocyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016353348A1 true AU2016353348A1 (en) | 2018-07-05 |
Family
ID=58696139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016353348A Abandoned AU2016353348A1 (en) | 2015-11-13 | 2016-11-11 | Heterocyclic compounds for the treatment of disease |
| AU2021202945A Active AU2021202945B2 (en) | 2015-11-13 | 2021-05-10 | Heterocyclic compounds for the treatment of disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021202945A Active AU2021202945B2 (en) | 2015-11-13 | 2021-05-10 | Heterocyclic compounds for the treatment of disease |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10683291B2 (https=) |
| EP (2) | EP4163281A1 (https=) |
| JP (3) | JP6933384B2 (https=) |
| KR (1) | KR102720397B1 (https=) |
| CN (2) | CN108463222B (https=) |
| AU (2) | AU2016353348A1 (https=) |
| BR (1) | BR112018009745B1 (https=) |
| CA (1) | CA3005236C (https=) |
| DK (1) | DK3373931T3 (https=) |
| ES (1) | ES2932049T3 (https=) |
| HR (1) | HRP20221417T1 (https=) |
| HU (1) | HUE060594T2 (https=) |
| IL (1) | IL259297B2 (https=) |
| LT (1) | LT3373931T (https=) |
| MX (1) | MX382092B (https=) |
| PL (1) | PL3373931T3 (https=) |
| PT (1) | PT3373931T (https=) |
| RS (1) | RS63837B1 (https=) |
| RU (1) | RU2727194C2 (https=) |
| SI (1) | SI3373931T1 (https=) |
| SM (1) | SMT202300062T1 (https=) |
| WO (1) | WO2017083756A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3373931T3 (da) | 2015-11-13 | 2022-11-28 | Oppilan Pharma Ltd | Heterocykliske forbindelser til behandling af sygdom |
| US20210163485A1 (en) * | 2017-05-17 | 2021-06-03 | Oppilan Pharma Ltd. | Heterocyclic Compounds for the Treatment of Disease |
| US20200071327A1 (en) * | 2017-05-17 | 2020-03-05 | Oppilan Pharma Ltd. | Prodrugs for the Treatment of Disease |
| GB201815018D0 (en) * | 2018-09-14 | 2018-10-31 | Univ Oxford Innovation Ltd | Enantiomeric compounds |
| CN119836422A (zh) | 2022-07-06 | 2025-04-15 | 奥比兰制药有限公司 | S1p受体调节剂的结晶形式 |
| CN120835886A (zh) * | 2023-01-13 | 2025-10-24 | 奥比兰制药有限公司 | S1p受体调节剂的制备 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772597A (en) * | 1983-10-14 | 1988-09-20 | Pfizer Inc. | 2-azacycloalkylthiopenem derivatives |
| CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| GB0511684D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| BRPI0612028A2 (pt) * | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| RU2425832C2 (ru) * | 2006-04-03 | 2011-08-10 | Астеллас Фарма Инк. | Гетеросоединение |
| SG177221A1 (en) | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| US20100160369A1 (en) * | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| WO2010117662A1 (en) | 2009-03-30 | 2010-10-14 | Exelixis, Inc. | Modulators of s1p and methods of making and using |
| US9011494B2 (en) | 2009-09-24 | 2015-04-21 | Warsaw Orthopedic, Inc. | Composite vertebral rod system and methods of use |
| NZ599913A (en) | 2009-11-13 | 2014-08-29 | Receptos Inc | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| JP5788507B2 (ja) * | 2010-07-20 | 2015-09-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換３−フェニル−１，２，４−オキサジアゾール化合物 |
| RU2014120180A (ru) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и аналоги в качестве модуляторов сиртуина |
| WO2015078374A1 (en) * | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| DK3373931T3 (da) | 2015-11-13 | 2022-11-28 | Oppilan Pharma Ltd | Heterocykliske forbindelser til behandling af sygdom |
-
2016
- 2016-11-11 DK DK16865156.0T patent/DK3373931T3/da active
- 2016-11-11 ES ES16865156T patent/ES2932049T3/es active Active
- 2016-11-11 HU HUE16865156A patent/HUE060594T2/hu unknown
- 2016-11-11 KR KR1020187016508A patent/KR102720397B1/ko active Active
- 2016-11-11 HR HRP20221417TT patent/HRP20221417T1/hr unknown
- 2016-11-11 SM SM20230062T patent/SMT202300062T1/it unknown
- 2016-11-11 AU AU2016353348A patent/AU2016353348A1/en not_active Abandoned
- 2016-11-11 SI SI201631650T patent/SI3373931T1/sl unknown
- 2016-11-11 CN CN201680078856.8A patent/CN108463222B/zh active Active
- 2016-11-11 IL IL259297A patent/IL259297B2/en unknown
- 2016-11-11 RS RS20221070A patent/RS63837B1/sr unknown
- 2016-11-11 BR BR112018009745-4A patent/BR112018009745B1/pt active IP Right Grant
- 2016-11-11 PT PT168651560T patent/PT3373931T/pt unknown
- 2016-11-11 MX MX2018005987A patent/MX382092B/es unknown
- 2016-11-11 WO PCT/US2016/061676 patent/WO2017083756A1/en not_active Ceased
- 2016-11-11 EP EP22195151.0A patent/EP4163281A1/en active Pending
- 2016-11-11 PL PL16865156.0T patent/PL3373931T3/pl unknown
- 2016-11-11 JP JP2018545102A patent/JP6933384B2/ja active Active
- 2016-11-11 CN CN202111183182.7A patent/CN114149424B/zh active Active
- 2016-11-11 CA CA3005236A patent/CA3005236C/en active Active
- 2016-11-11 US US15/775,723 patent/US10683291B2/en active Active
- 2016-11-11 LT LTEPPCT/US2016/061676T patent/LT3373931T/lt unknown
- 2016-11-11 EP EP16865156.0A patent/EP3373931B1/en active Active
- 2016-11-11 RU RU2018121416A patent/RU2727194C2/ru active
-
2020
- 2020-05-01 US US16/865,212 patent/US20200325135A1/en not_active Abandoned
-
2021
- 2021-05-10 AU AU2021202945A patent/AU2021202945B2/en active Active
- 2021-08-11 JP JP2021131351A patent/JP7174963B2/ja active Active
-
2022
- 2022-03-18 US US17/698,991 patent/US20220227767A1/en not_active Abandoned
- 2022-10-28 JP JP2022173717A patent/JP7445325B2/ja active Active
-
2023
- 2023-06-29 US US18/344,594 patent/US20230339944A1/en not_active Abandoned
-
2025
- 2025-05-14 US US19/207,818 patent/US20260092064A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202945B2 (en) | Heterocyclic compounds for the treatment of disease | |
| ES2565229T3 (es) | Derivados 2-amino-4-(piridin-2-il)-5,6-dihidro-4H-1,3-oxazina y su uso como inhibidores de BACE-1 y/o BACE-2 | |
| WO2016022460A1 (en) | Potent dual brd4-kinase inhibitors as cancer therapeutics | |
| WO2017066428A1 (en) | Brd4-kinase inhibitors as cancer therapeutics | |
| KR20130046436A (ko) | 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도 | |
| JP2021524469A (ja) | Ｎｒｆ２アクチベーターとしてのインダン | |
| WO2018211323A1 (en) | Hetercyclic compounds for the treatment of disease | |
| EP3625230A1 (en) | Prodrugs for the treatment of disease | |
| WO2020205835A1 (en) | Fused polycyclic pyridone compounds as influenza virus replication inhibitors | |
| HK40070316A (en) | Heterocyclic compounds for the treatment of disease | |
| HK1260375B (zh) | 用於治疗疾病的杂环化合物 | |
| HK40070316B (zh) | 用於治疗疾病的杂环化合物 | |
| HK1260375A1 (en) | Heterocyclic compounds for the treatment of disease | |
| CA3181577A1 (en) | Thieno pyrimidines as ferroportin inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |